Enobia Pharma Announces the Appointment of Dr. Robert Heft as Chief Executive Officer
November 24, 2005
Montreal, Quebec, CANADA – November 24, 2005 – Enobia Pharma, announced today that it has appointed Dr. Robert Heft as the Company’s President and Chief Executive Officer.
“As Enobia focuses its Strategic Plan and prepares to bring its first compound into the clinic, we welcome the leadership and experience that Dr. Heft brings to the Company”, stated Yvon Bastien, Chairman of the Enobia Board of Directors.
“Enobia’s technology has the potential to greatly alleviate the suffering associated with several serious bone related disorders and the Company has been successful in attracting the commitment and confidence of a strong investor base. I look forward to being part of this team,” Robert Heft stated.
Dr. Heft, has 20 years experience in the biopharmaceutical industry.
From 2001 through 2004, Dr. Heft served as Vice-President Product Development with BioMarin Pharmaceutical Inc. (Nasdaq and SWX:BMRN, Novato, California) after BioMarin acquired the pharmaceutical assets of IBEX Technologies Inc. While at BioMarin, the company completed the clinical development of two Enzyme Replacement Therapeutics, and launched the first of them, Aldurazyme, for the treatment of MPS1.
Prior to joining BioMarin, Dr. Heft was President of IBEX Technologies Inc. (TSX:IBT, Montreal), a company he founded focused on the development of enzyme based therapeutics for heparin neutralization and the treatment of Phenylkeonuria (PKU). Prior to IBEX, Dr. Heft served as Research Director for Continental Pharma.
Dr. Heft received a PhD in Genetic Engineering/Radiological Sciences from the Massachusetts Institute of Technology in 1986, a Master in Nuclear Engineering from Cornell University and a Bachelor in Engineering from McGill University.
Dr. Heft has served as a Director of the Industrial Biotechnology Association of Canada, the Canadian Genetic Disease Network and BioCapital, a venture capital fund.
About Enobia Pharma
Enobia Pharma is a Montreal based, privately held company founded in 1997. The Company is developing Enzyme Replacement Therapeutics and other compounds for the treatment of serious bone diseases. Enobia Pharma has recently completed a $19M round of financing with Desjardins Capital de Risque, Fonds de solidarité FTQ, Lothian Partner and T2C2/Bio.
Its website address is www.enobia.com.
For additional information on Enobia Pharma, please contact:
Mr. Luc Cournoyer, Vice-president Finance and administration
Enobia Pharma
2901 Rachel Street East, Suite 23, Montreal, Quebec, CANADA.H1W 4A4
(514) 596-2901 extension # 223
Email: luc.cournoyer@enobia.com
Back